The pCR benefit was generally consistent across pre-specified subgroups including tumor PD-L1 status (CPS ≥ 1 versus <1), lymph nodes involvement, and estrogen receptor (ER) positivity (≥10% versus 1–9%). The gene discussed is ESR1; the disease is neoplasm.